Literature DB >> 8508005

Clinical features of type III hyperlipoproteinemia: analysis of 64 patients.

G Feussner1, A Wagner, B Kohl, R Ziegler.   

Abstract

The clinical and biochemical characteristics of type III hyperlipoproteinemia are described in 64 patients (35 males and 29 females). Homozygosity for apolipoprotein E2, the presence of an abnormally cholesterol-rich very low density lipoprotein fraction (beta-VLDL) and an elevated ratio of very low density lipoprotein cholesterol to plasma triglycerides (> 0.3; normal ratio about 0.2) were the basis for the diagnosis. Mean serum cholesterol and triglyceride concentrations at the first visit in the clinic were 426 +/- 221 and 719 +/- 996 mg/dl, respectively. The mean age at diagnosis of the disorder was 49 years in males and 53 years in females. There was a high prevalence of obesity (72%), xanthomas (42%), and atherosclerosis (39%), especially peripheral vascular disease (31%). Early and correct diagnosis of this familial lipoprotein disorder seems necessary because of the prompt and beneficial response to therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508005     DOI: 10.1007/BF00186624

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  33 in total

1.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

2.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

3.  Type 3 hyperlipoproteinaemia.

Authors:  P Borrie
Journal:  Br Med J       Date:  1969-06-14

4.  Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology.

Authors:  R W Mahley
Journal:  Circulation       Date:  1985-11       Impact factor: 29.690

5.  Clinical features of type III hyperlipoproteinaemia.

Authors:  P M Stuyt; A Van 't Laar
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

6.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

Authors:  K H Weisgraber; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

Review 7.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 8.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

Authors:  T L Innerarity; R W Mahley; K H Weisgraber; T P Bersot; R M Krauss; G L Vega; S M Grundy; W Friedl; J Davignon; B J McCarthy
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

9.  Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin.

Authors:  C A East; S M Grundy; D W Bilheimer
Journal:  Metabolism       Date:  1986-02       Impact factor: 8.694

10.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

View more
  8 in total

1.  Severe xanthomatosis associated with familial apolipoprotein E deficiency.

Authors:  G Feussner
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  The relative atherogenicity of VLDL and LDL is dependent on the topographic site.

Authors:  Eline Van Craeyveld; Frank Jacobs; Yingmei Feng; Leen C J Thomassen; Johan A Martens; Joke Lievens; Jan Snoeys; Bart De Geest
Journal:  J Lipid Res       Date:  2010-01-19       Impact factor: 5.922

Review 3.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 4.  Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.

Authors:  Murielle M Véniant; Anne P Beigneux; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

5.  A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia.

Authors:  G Feussner; J Dobmeyer; H J Gröne; S Lohmer; S Wohlfeil
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

6.  Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.

Authors:  Paul N Hopkins; M Nazeem Nanjee; Lily L Wu; Michael G McGinty; Eliot A Brinton; Steven C Hunt; Jeffrey L Anderson
Journal:  Atherosclerosis       Date:  2009-05-22       Impact factor: 5.162

7.  Increased Remnant Lipoproteins in Apo E Deficient Mice Induce Coronary Atherosclerosis following Transverse Aortic Constriction and Aggravate the Development of Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure.

Authors:  Ilayaraja Muthuramu; Mudit Mishra; Bart De Geest
Journal:  Biomedicines       Date:  2022-07-04

8.  Regional Variation in Genetic Control of Atherosclerosis in Hyperlipidemic Mice.

Authors:  Michael B Jones; Alexander An; Lisa J Shi; Weibin Shi
Journal:  G3 (Bethesda)       Date:  2020-12-03       Impact factor: 3.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.